Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.
about
Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activitiesIn vitro metabolism and drug interaction potential of a new highly potent anti-cytomegalovirus molecule, CMV423 (2-chloro 3-pyridine 3-yl 5,6,7,8-tetrahydroindolizine I-carboxamide)Extrapolating in vitro data on drug metabolism to in vivo pharmacokinetics: evaluation of the pharmacokinetic interaction between amitriptyline and fluoxetine.The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms.A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction predictionThe role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition.Effect of hepatic function on the EC50 of midazolam and the BIS50 at the time of loss of consciousness.The human CYP3A subfamily: practical considerations.A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.Human drug metabolism and the cytochromes P450: application and relevance of in vitro models.Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifeneIn vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine.Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjectsSerum alanine transaminase total bilirubin concentrations predict CYP3A activity as measured by midazolam and 1'-hydroxylation.Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients.The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjectsThe role of CYP2C and CYP3A in the disposition of 3-keto-desogestrel after administration of desogestrelEffect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1'-hydroxylation.Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.CYP3A-dependent drug metabolism is reduced in bacterial inflammation in miceRole of efflux pumps and metabolising enzymes in drug delivery.Impact of organic solvents on cytochrome P450 probe reactions: filling the gap with (S)-Warfarin and midazolam hydroxylationMidazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymesMetabolic drug interactions with newer antipsychotics: a comparative review.Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.Physiological endpoints for potential SSRI interactions in fish.Incidence rate and pattern of clinically relevant potential drug-drug interactions in a large outpatient population of a developing country.Inhibition and induction of human cytochrome P450 enzymes: current status.The structural basis for homotropic and heterotropic cooperativity of midazolam metabolism by human cytochrome P450 3A4.Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.Changes in IL-2 and IL-10 during Chronic Administration of Isoniazid, Nevirapine, and Paracetamol in Rats.Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity.In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.In vitro approaches to investigate cytochrome P450 activities: update on current status and their applicability.Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination.Integration of in vitro binding mechanism into the semiphysiologically based pharmacokinetic interaction model between ketoconazole and midazolam.Effect of multiple doses of montelukast on the pharmacokinetics of rosiglitazone, a CYP2C8 substrate, in humansInhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies.
P2860
Q28269209-0F0A7491-D429-41DE-AA88-70077529E175Q28343857-4022B72B-0E2E-4931-8CBF-B1D52FE93681Q30577448-8AC1AE60-164C-46AC-BC3E-8D522A74590BQ33254664-FCBBED26-E957-4C5F-9815-D9D18D3D8064Q33383326-FF2737D9-36CD-4C0F-A561-D66E514474B1Q33967634-8DEE3A02-9699-43F0-AE7B-D9DA032D3710Q34029472-6C5AEA54-70C7-4524-BA14-AA443B475B39Q34119161-9DAB38D9-830D-4FDD-B747-F8DF04C946F8Q34180397-44279A5B-31D6-470C-BABA-03DF85209232Q34430456-C5AFDEC6-0356-4DF8-9FE7-9AF85B5710ADQ34568883-E7121F80-D2EF-4402-987E-53B5056E78ABQ34746998-4C0CDDE0-4282-4DF5-AEFC-3A679BF483AEQ34829983-DBA0F0DA-D8B1-444E-883A-7736A2C53ECEQ35087638-4F7FA43C-12AF-4763-B129-69ED448D997CQ35825944-DC7E8FEF-714C-409A-A6C8-7B610360B720Q35826014-B33F95C6-0FE2-4855-9425-6117F0CD83BAQ35827129-556D8774-BF36-4EE9-AC3D-206EB6A22541Q36055339-4A2A8159-3A2D-40D0-A361-DBEA1A050A28Q36072448-0620614F-25AC-45C3-A656-417DE1483F8EQ36110529-1DA2ADC5-E0C7-4E55-A2D0-77200C8A1B2FQ36316872-B817904B-2E03-4119-B3A8-7B36FFE31736Q36335452-96CF034A-754D-4951-92D7-22062C343F58Q36667359-7F94CB00-A9B6-4321-8655-A5036A82AF12Q36703845-E1DE8C64-C088-43CA-A0BD-21428C7C5EC0Q36718456-F8227EBD-0C4A-4EBC-940D-34723FE7D796Q37072046-D9AA3443-DC91-4986-A12D-32A8BCD295F4Q37103805-E8D4B772-4864-4F3D-91C9-2D9C24811466Q37129099-EA940B72-6278-4BC3-AB73-BBBA2C4C1D48Q37212794-81EED2C2-93A3-40F4-8826-A38799E2ACCEQ37308650-8ECD46E6-6D00-4D63-893C-11D81F5B5154Q37325598-48766123-C1DF-48B9-8118-BF356AFDA9ECQ37470803-91A70778-AA50-403B-9312-D8335B71DFBBQ37780212-5ED7CA25-331C-46EF-8DF4-A2DDC6F18E75Q37845170-B4EEB239-8FA3-49E7-BFE5-F488DA777DA8Q37989979-1A05FCE6-93CB-42A0-B437-8791C23E1291Q38107523-F9EEDE20-F687-4DF0-B9B5-B5B014274009Q39149746-BC890B15-10FD-46F1-B18E-76BC6730FDAFQ39756295-EAEE50A2-7967-4ECD-90EE-A20CB8D3F810Q41124631-6F58FEAA-ABC4-479C-8434-D6868DC49AE9Q41186979-3CD132A5-6722-4969-8AB1-4572B41489E1
P2860
Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Midazolam hydroxylation by hum ...... nd by azole antifungal agents.
@en
Midazolam hydroxylation by hum ...... nd by azole antifungal agents.
@nl
type
label
Midazolam hydroxylation by hum ...... nd by azole antifungal agents.
@en
Midazolam hydroxylation by hum ...... nd by azole antifungal agents.
@nl
prefLabel
Midazolam hydroxylation by hum ...... nd by azole antifungal agents.
@en
Midazolam hydroxylation by hum ...... nd by azole antifungal agents.
@nl
P2093
P2860
P1476
Midazolam hydroxylation by hum ...... nd by azole antifungal agents.
@en
P2093
C E Wright
D J Greenblatt
J S Harmatz
J Schmider
L L von Moltke
R I Shader
P2860
P304
P356
10.1002/J.1552-4604.1996.TB04251.X
P577
1996-09-01T00:00:00Z